Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo Company has filed an Abbreviated New Drug Application (ANDA) with the US FDA for the generic version of Patanase nasal spray and has notified Alcon Laboratories which manufactures the spray.
Subscribe to our email newsletter
Alcon Labs had filed a lawsuit against Perrigo on 14 October 2011 alleging patent infringement.
Patanase (olopatadine hydrochloride) nasal spray helps provide relief from the symptoms of seasonal allergic rhinitis.
Perrigo chairman and CEO Joseph C Papa said the filing marks their investment in new products and expansion of product portfolio.